ResMed stock a buy despite Lilly impact: Barron’s (NYSE:RMD)
JHVEphoto Baron This week, he said that ResMed (NYSE:RMD) is trading at a compelling valuation after the stock sold off last month in response to Eli Lilly's positive data.NYSE:LLY) GLP-1 therapy, tirzepatide, in obstructive sleep…